Xiangbao Meng

Dr. Xiangbao Meng

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
MZMingxia Zhao
Mingxia Zhao
WGWenjie Guo
Wenjie Guo
YWYuanyuan Wu
Yuanyuan Wu
CYChenxi Yang
Chenxi Yang
LZLiang Zhong
Liang Zhong
Yang SunYang Sun
Yang Sun
Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation. Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo. However, whether SHP099-mediated SHP2 inhibition retards tumor growth in vivo via anti-tumor immunity remains elusive. To address this, a CT-26 colon cancer xenograft model was established in mice since this cell line is insensitive to SHP099. Consequently, SHP099 minimally affected CT-26 tumor growth in immuno-deficient nude mice, but significantly decreased the tumor burden in CT-26 tumor-bearing mice with intact immune system. SHP099 augmented anti-tumor immunity, as shown by the elevated proportion of CD8+IFN-γ + T cells and the upregulation of cytotoxic T-cell related genes including Granzyme B andPerforin, which decreased the tumor load. In addition, tumor growth in mice with SHP2-deficient T-cells was markedly slowed down because of enhanced anti-tumor responses. Finally, the combination of SHP099 and anti-PD-1 antibody showed a higher therapeutic efficacy than either monotherapy in controlling tumor growth in two colon cancer xenograft models, indicating that these agents complement each other. Our study suggests that SHP2 inhibitor SHP099 is a promising candidate drug for cancer immunotherapy.

1 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMingming Zhao
Mingming Zhao
HWHaoran Wei
Haoran Wei
CLChenze Li
Chenze Li
RZRui Zhan
Rui Zhan
CLChangjie Liu
Changjie Liu
Lemin ZhengLemin Zheng
Lemin Zheng
Numerous studies found intestinal microbiota alterations which are thought to affect the development of various diseases through the production of gut-derived metabolites. However, the specific metabolites and their pathophysiological contribution to cardiac hypertrophy or heart failure progression still remain unclear. N,N,N-trimethyl-5-aminovaleric acid (TMAVA), derived from trimethyllysine through the gut microbiota, was elevated with gradually increased risk of cardiac mortality and transplantation in a prospective heart failure cohort (n = 1647). TMAVA treatment aggravated cardiac hypertrophy and dysfunction in high-fat diet-fed mice. Decreased fatty acid oxidation (FAO) is a hallmark of metabolic reprogramming in the diseased heart and contributes to impaired myocardial energetics and contractile dysfunction. Proteomics uncovered that TMAVA disturbed cardiac energy metabolism, leading to inhibition of FAO and myocardial lipid accumulation. TMAVA treatment altered mitochondrial ultrastructure, respiration and FAO and inhibited carnitine metabolism. Mice with γ-butyrobetaine hydroxylase (BBOX) deficiency displayed a similar cardiac hypertrophy phenotype, indicating that TMAVA functions through BBOX. Finally, exogenous carnitine supplementation reversed TMAVA induced cardiac hypertrophy. These data suggest that the gut microbiota-derived TMAVA is a key determinant for the development of cardiac hypertrophy through inhibition of carnitine synthesis and subsequent FAO.

28 August 2012 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
ZLZhi-Qi Lao
Zhi-Qi Lao
WZWen-He Zhong
Wen-He Zhong
QLQing-Hua Lou
Qing-Hua Lou
ZLZhongjun Li
Zhongjun Li
XMXiangbao Meng
Xiangbao Meng
We have developed a new KI-catalyzed method for the imidation of an sp3 C–H bond adjacent to an amide nitrogen atom by using TBHP (tert-butyl hydroperoxide, 70% aqueous solution) as the oxidant. This novel procedure tolerated air and moisture and provided a series of novel products in moderate to excellent yields under mild conditions.

12 September 2012 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
QWQing Wang
Qing Wang
WZWenhe Zhong
Wenhe Zhong
XWXiong Wei
Xiong Wei
MNMaoheng Ning
Maoheng Ning
XMXiangbao Meng
Xiangbao Meng
ZLZhongjun Li
Zhongjun Li
A convenient, metal-free intramolecular aminofluorination of alkenes has been developed. Employing readily available PhI(OPiv)2 and hydrogen fluoride–pyridine in the presence of BF3·OEt2, tosyl-protected pent-4-en-1-amines were converted to 3-F-piperidines in one step in good yields as well as high stereoselectivity.

15 October 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
WLWen Liu
Wen Liu
WGWenjie Guo
Wenjie Guo
YZYongcheng Zhu
Yongcheng Zhu
SPShuang Peng
Shuang Peng
WZWei Zheng
Wei Zheng
Yang SunYang Sun
Yang Sun
Aberrant activation of the NLRP3 inflammasome contributes to the onset and progression of various inflammatory diseases, making it a highly desirable drug target. In this study, we screened a series of small compounds with anti-inflammatory activities and identified a novel NLRP3 inflammasome inhibitor, AI-44, a curcumin analogue that selectively inhibited signal 2 but not signal 1 of NLRP3 inflammasome activation. We demonstrated that AI-44 bound to peroxiredoxin 1 (PRDX1) and promoted the interaction of PRDX1 with pro–Caspase-1 (CASP1), which led to the suppression of association of pro-CASP1 and ASC. Consequently, the assembly of the NLRP3 inflammasome was interrupted, and the activation of CASP1 was inhibited. Knockdown of PRDX1 significantly abrogated the inhibitory effect of AI-44 on the NLRP3 inflammasome. Importantly, AI-44 alleviated LPS-induced endotoxemia in mice via suppressing NLRP3 inflammasome activation. Taken together, our work highlighted PRDX1 as a negative regulator of NLRP3 inflammasome activation and suggested AI-44 as a promising candidate compound for the treatment of sepsis or other NLRP3 inflammasome-driven diseases.

1 July 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CZChao Zhang
Chao Zhang
BZBo Zhong
Bo Zhong
SYSimin Yang
Simin Yang
LPLiangkun Pan
Liangkun Pan
SYSiwang Yu
Siwang Yu
XMXiangbao Meng
Xiangbao Meng